Rocbrutinib is an orally available, highly selective Brutons tyrosine kinase (BTK) inhibitor, with an IC50 of 0.11 nM against wild-type BTK and an IC50 of 1.0 nM against C481S-mutated BTK. Rocbrutinib reduces the viability of leukemia cells, induces cytotoxicity and inhibits cell migration. Rocbrutinib can be used in research related to chronic lymphocytic leukemia, non-Hodgkins lymphoma and mantle cell lymphoma[1][2].
Molecular Weight:
761.91
Purity:
99.76
CAS Number:
[2485861-07-0]
Formula:
C42H51N9O5
Target:
EGFR
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted